| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| Targets |
EGTA does not have a biological target in the traditional sense. Its "target" is the calcium ion (Ca²⁺). By selectively chelating Ca²⁺, EGTA can modulate calcium-dependent signaling pathways and processes. It is used as a tool to study the role of calcium in various cellular functions, such as muscle contraction, neurotransmission, and cell signaling.
|
|---|---|
| ln Vitro |
It is suggested that EGTA be used as a pulp irrigant, which decreases inflammatory macrophages' ability to adhere to substrate in a dose- and time-dependent way. 202 mM was the EGTA concentration at which an IC50 was obtained. Metal chelates are created when the chelating agent interacts with the calcium ions in the hydroxyapatite crystals. The dentin tissue, particularly the hydroxyapatite-rich peritubular dentin, becomes softer when calcium ions are removed from it, and the diameter of the exposed dentinal tubules rises [2].
In vitro, EGTA is used to chelate calcium ions in cell-free and cell-based systems. By depleting extracellular calcium, it can inhibit calcium-dependent processes like cell adhesion and receptor-mediated signaling. It is a standard reagent for preparing calcium-free buffers and for studying the role of calcium in enzyme activity and protein function. |
| ln Vivo |
In vivo, EGTA can be administered to animals to induce acute hypocalcemia and study its effects on various physiological processes. For example, it can be used to investigate the role of calcium in cardiac function, neurotransmitter release, and blood clotting. However, its use in vivo is primarily for research purposes and not for therapeutic intervention.
|
| Enzyme Assay |
In a typical non-cellular assay, EGTA is used in a buffer system (e.g., Tris-HCl, pH 7.4) to chelate Ca²⁺ and other divalent cations. Its ability to bind Ca²⁺ can be measured using a calcium ion-selective electrode or by using a fluorescent calcium indicator like Fluo-4. The binding affinity (Kd) for Ca²⁺ is approximately 10⁻¹¹ M under physiological conditions. Controls include buffers without EGTA and with known concentrations of Ca²⁺ to construct a calibration curve.
|
| Cell Assay |
In cell culture, EGTA is added to the medium to chelate extracellular calcium. For example, cells can be treated with EGTA (e.g., 1-5 mM) in a calcium-free buffer to disrupt cell-cell and cell-matrix adhesions, which is a common step in cell dissociation protocols. It is also used to study calcium-dependent signaling pathways by removing extracellular calcium and observing the effect on cellular responses.
|
| Animal Protocol |
In animal studies, EGTA is often administered via injection (e.g., intravenous) to induce hypocalcemia. For example, in rats or mice, an infusion of EGTA can be used to study the role of calcium in cardiac contractility or in the release of hormones like insulin. Blood calcium levels are monitored to confirm the effectiveness of the chelation.
|
| ADME/Pharmacokinetics |
EGTA is not a drug and is not subject to standard pharmacokinetic analysis. When administered in vivo, it distributes in the extracellular space and acts by chelating calcium in the blood. It is rapidly excreted by the kidneys. Its half-life is short, and its effects are reversible upon cessation of administration.
|
| Toxicity/Toxicokinetics |
The toxicological profile of EGTA is primarily related to its ability to chelate calcium. Acute administration can cause hypocalcemia, which can lead to muscle cramps, cardiac arrhythmias, and other serious effects. It is for research use only and is not intended for human consumption. Standard laboratory safety precautions should be followed.
|
| References |
|
| Additional Infomation |
Ethylene glycol bis(2-aminoethyl)tetraacetic acid (EDTA) is a diether formed by replacing the hydrogen atom on the hydroxyl group of an ethylene glycol molecule with a 2-[bis(carboxymethyl)amino]ethyl group. It is a chelating agent. It is a tetracarboxylic acid, a tertiary amine compound, and a diether. Compared to ethylenediaminetetraacetic acid (EDTA), it is a chelating agent with higher specificity for calcium ions and lower toxicity.
EGTA is not a drug. It is a widely used research reagent, specifically a selective calcium chelator. It is a cornerstone tool in cell biology, physiology, and biochemistry for studying calcium's role in countless biological processes. It is not approved for any clinical use. |
| Molecular Formula |
C14H24N2O10
|
|---|---|
| Molecular Weight |
380.35
|
| Exact Mass |
380.143
|
| CAS # |
67-42-5
|
| Related CAS # |
EGTA tetrasodium;13368-13-3
|
| PubChem CID |
6207
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
678.0±55.0 °C at 760 mmHg
|
| Melting Point |
241 °C (dec.)(lit.)
|
| Flash Point |
363.9±31.5 °C
|
| Vapour Pressure |
0.0±4.5 mmHg at 25°C
|
| Index of Refraction |
1.547
|
| LogP |
-2.53
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
26
|
| Complexity |
397
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(COCCOCCN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O
|
| InChi Key |
DEFVIWRASFVYLL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H24N2O10/c17-11(18)7-15(8-12(19)20)1-3-25-5-6-26-4-2-16(9-13(21)22)10-14(23)24/h1-10H2,(H,17,18)(H,19,20)(H,21,22)(H,23,24)
|
| Chemical Name |
2-[2-[2-[2-[bis(carboxymethyl)amino]ethoxy]ethoxy]ethyl-(carboxymethyl)amino]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 5 mg/mL (13.15 mM)
DMSO: 1 mg/mL (2.63 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6292 mL | 13.1458 mL | 26.2916 mL | |
| 5 mM | 0.5258 mL | 2.6292 mL | 5.2583 mL | |
| 10 mM | 0.2629 mL | 1.3146 mL | 2.6292 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
